Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
Reduced appetite, which is a therapeutic effect, not a side effect
Mexican Chem
Accessible labels and containers If your prescription label is hard to read, talk with your doctor or pharmacist
Acne Changing hormone levels may have brought on zits during puberty, and it can do the same during perimenopause
Weight Loss by Hers is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you
-1.png)
